DK1023074T3 - Fremgangsmåder til behandling af psykose forbundet med glucocorticoid-relateret dysfunktion - Google Patents
Fremgangsmåder til behandling af psykose forbundet med glucocorticoid-relateret dysfunktionInfo
- Publication number
- DK1023074T3 DK1023074T3 DK98950911T DK98950911T DK1023074T3 DK 1023074 T3 DK1023074 T3 DK 1023074T3 DK 98950911 T DK98950911 T DK 98950911T DK 98950911 T DK98950911 T DK 98950911T DK 1023074 T3 DK1023074 T3 DK 1023074T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- glucocorticoid
- psychosis associated
- treating psychosis
- related dysfunction
- Prior art date
Links
- 208000028017 Psychotic disease Diseases 0.000 title abstract 2
- 230000004064 dysfunction Effects 0.000 title 1
- 239000003862 glucocorticoid Substances 0.000 title 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 229960003248 mifepristone Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6097397P | 1997-10-06 | 1997-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1023074T3 true DK1023074T3 (da) | 2006-11-06 |
Family
ID=22032889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98950911T DK1023074T3 (da) | 1997-10-06 | 1998-10-05 | Fremgangsmåder til behandling af psykose forbundet med glucocorticoid-relateret dysfunktion |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6150349A (https=) |
| EP (1) | EP1023074B1 (https=) |
| JP (3) | JP2001518509A (https=) |
| KR (2) | KR100840957B1 (https=) |
| CN (3) | CN1528315A (https=) |
| AT (1) | ATE332696T1 (https=) |
| AU (1) | AU747956B2 (https=) |
| CA (1) | CA2302586C (https=) |
| CY (1) | CY1106330T1 (https=) |
| DE (1) | DE69835225T2 (https=) |
| DK (1) | DK1023074T3 (https=) |
| ES (1) | ES2268792T3 (https=) |
| IL (2) | IL135469A0 (https=) |
| NO (1) | NO327233B1 (https=) |
| NZ (1) | NZ503250A (https=) |
| PT (1) | PT1023074E (https=) |
| WO (1) | WO1999017779A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0903146A1 (en) * | 1997-09-23 | 1999-03-24 | Applied Research Systems ARS Holdings N.V. | 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid |
| GB9915625D0 (en) * | 1999-07-02 | 1999-09-01 | Cortendo Ab | Method |
| US6620802B1 (en) | 1999-11-23 | 2003-09-16 | Corcept Therapeutics, Inc. | Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist |
| US7071328B2 (en) * | 2000-09-18 | 2006-07-04 | Applied Research System Ars Holding N.V. | Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21 oh-6op) |
| DE60232956D1 (de) | 2001-03-23 | 2009-08-27 | Corcept Therapeutics Inc | Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten |
| WO2002096433A1 (en) * | 2001-05-04 | 2002-12-05 | Corcept Therapeutics, Inc. | Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| US7163934B2 (en) | 2001-05-04 | 2007-01-16 | Corcept Therapeutics, Inc. | Methods for treating delirium glucocorticoid receptor-specific antagonists |
| CA2454339C (en) | 2001-07-23 | 2012-01-10 | Corcept Therapeutics, Inc. | Methods for preventing antipsychotic-induced weight gain |
| NZ531477A (en) * | 2001-08-31 | 2006-10-27 | Corcept Therapeutics Inc | Use of a glucocorticoid receptor antagonist comprising a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton to decrease cognitive deterioration in adults with Down's syndrome |
| DE60230936D1 (de) * | 2001-10-26 | 2009-03-05 | Organon Nv | Verwendung von (11beta, 17beta)-11-(1,3-Benzodioxol-5-yl)-17-Hydroxy-17-(1-Propinyl)-estra-4,9-dien-3-on zur Behandlung von schweren Depressionen |
| AU2002366217A1 (en) * | 2001-11-23 | 2003-06-10 | Akzo Nobel N.V. | Treatment of major depressive disorder using glucocorticoid receptor antagonists |
| US7326697B2 (en) * | 2002-04-29 | 2008-02-05 | Corcept Therapeutics, Inc. | Methods for increasing the therapeutic response to electroconvulsive therapy |
| JP2005535664A (ja) * | 2002-07-02 | 2005-11-24 | コーセプト セラピューティクス， インコーポレイテッド | インターフェロン−α治療に関連した精神病を処置するための方法 |
| WO2004054587A1 (en) * | 2002-12-18 | 2004-07-01 | University Of Zurich | Treatment of neuro-psychiatric disorders |
| JP2006516651A (ja) * | 2003-02-04 | 2006-07-06 | コーセプト セラピューティクス， インコーポレイテッド | 産後精神病の処置のための抗糖質コルチコイド |
| US8097606B2 (en) * | 2003-07-23 | 2012-01-17 | Corcept Therapeutics, Inc. | Antiglucocorticoids for the treatment of catatonia |
| GB0400031D0 (en) | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
| US20090156565A1 (en) * | 2004-12-03 | 2009-06-18 | The Children's Hospital Of Philadelphia | Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug |
| CN100588393C (zh) * | 2004-12-15 | 2010-02-10 | 上海三合生物技术有限公司 | 赛米司酮类用于治疗抑郁症的用途 |
| US20060229505A1 (en) * | 2005-04-08 | 2006-10-12 | Mundt James C | Method and system for facilitating respondent identification with experiential scaling anchors to improve self-evaluation of clinical treatment efficacy |
| WO2007131041A2 (en) * | 2006-05-02 | 2007-11-15 | Corcept Therapeutics, Inc. | The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2 |
| EP1987814A1 (en) * | 2007-04-30 | 2008-11-05 | Exelgyn | Mifepristone pharmaceutical compositions and their methods of preparation |
| RU2327448C1 (ru) | 2007-05-23 | 2008-06-27 | Виктор Иванович Рощин | Средство для лечения зависимости от этилового спирта и/или от наркотиков, фармацевтическая композиция, активный ингредиент фармацевтической композиции, способ лечения зависимости от этилового спирта и/или от наркотиков для лечения психосоматических и неврологических осложнений у алкоголиков и/или наркоманов |
| WO2008157460A1 (en) * | 2007-06-15 | 2008-12-24 | Cook, Kevin, M. | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| WO2011150209A1 (en) * | 2010-05-26 | 2011-12-01 | Corcept Therapeutics, Inc. | Treatment of muscular dystrophy |
| WO2012106514A2 (en) | 2011-02-03 | 2012-08-09 | Pop Test Cortisol Llc | System and method for diagnosis and treatment |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| US8986677B2 (en) * | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
| AU2016226451B2 (en) * | 2015-03-02 | 2019-12-19 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors |
| US9943526B2 (en) | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
| KR20180008627A (ko) * | 2015-05-18 | 2018-01-24 | 코어셉트 쎄라퓨틱스, 잉크. | 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법 |
| CN114680890A (zh) * | 2016-10-21 | 2022-07-01 | 西铁城时计株式会社 | 检测装置 |
| EP4653047A3 (en) | 2019-03-18 | 2026-02-18 | Nieman, Lynnette K. | Mifepristone for use in improving insulin sensitivity |
| JP7569492B2 (ja) | 2019-12-11 | 2024-10-18 | コーセプト セラピューティクス， インコーポレイテッド | 抗精神病薬誘発性体重増加のミリコリラントによる治療方法 |
| US11878025B2 (en) * | 2021-09-06 | 2024-01-23 | Slayback Pharma Llc | Pharmaceutical compositions of mifepristone |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| US5348729A (en) * | 1988-11-30 | 1994-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Evaluative means for detecting inflammatory reactivity |
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| IL118974A (en) * | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
| FR2739029B1 (fr) * | 1995-09-21 | 1997-11-21 | Roussel Uclaf | Nouvelle application therapeutique des composes antimineralo-corticoides |
| EP0954317B1 (en) * | 1996-04-09 | 2007-06-06 | The University Of Edinburgh | Use of 7 apha-substituted steroids to treat neuropsychiatric disorders |
| FR2757400B1 (fr) * | 1996-12-19 | 1999-12-17 | Hoechst Marion Roussel Inc | Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs |
-
1998
- 1998-10-05 AU AU96832/98A patent/AU747956B2/en not_active Ceased
- 1998-10-05 AT AT98950911T patent/ATE332696T1/de active
- 1998-10-05 WO PCT/US1998/020906 patent/WO1999017779A1/en not_active Ceased
- 1998-10-05 CN CNA200410039908XA patent/CN1528315A/zh active Pending
- 1998-10-05 NZ NZ503250A patent/NZ503250A/en not_active IP Right Cessation
- 1998-10-05 IL IL13546998A patent/IL135469A0/xx active IP Right Grant
- 1998-10-05 CA CA002302586A patent/CA2302586C/en not_active Expired - Fee Related
- 1998-10-05 PT PT98950911T patent/PT1023074E/pt unknown
- 1998-10-05 EP EP98950911A patent/EP1023074B1/en not_active Expired - Lifetime
- 1998-10-05 JP JP2000514650A patent/JP2001518509A/ja not_active Withdrawn
- 1998-10-05 ES ES98950911T patent/ES2268792T3/es not_active Expired - Lifetime
- 1998-10-05 DE DE69835225T patent/DE69835225T2/de not_active Expired - Lifetime
- 1998-10-05 KR KR1020077003769A patent/KR100840957B1/ko not_active Expired - Fee Related
- 1998-10-05 CN CNB988097923A patent/CN1187053C/zh not_active Expired - Fee Related
- 1998-10-05 KR KR1020007003683A patent/KR100804558B1/ko not_active Expired - Fee Related
- 1998-10-05 DK DK98950911T patent/DK1023074T3/da active
- 1998-10-05 CN CNA2006101003657A patent/CN1919199A/zh active Pending
-
1999
- 1999-02-04 US US09/244,457 patent/US6150349A/en not_active Expired - Lifetime
-
2000
- 2000-04-04 IL IL135469A patent/IL135469A/en not_active IP Right Cessation
- 2000-04-05 NO NO20001744A patent/NO327233B1/no not_active IP Right Cessation
- 2000-08-15 US US09/639,377 patent/US6362173B1/en not_active Expired - Lifetime
-
2006
- 2006-10-05 CY CY20061101439T patent/CY1106330T1/el unknown
-
2008
- 2008-10-21 JP JP2008271442A patent/JP2009051858A/ja not_active Withdrawn
-
2009
- 2009-03-23 JP JP2009071039A patent/JP5180125B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NO327233B1 (no) | 2009-05-18 |
| PT1023074E (pt) | 2006-12-29 |
| CA2302586C (en) | 2008-06-10 |
| DE69835225T2 (de) | 2007-07-05 |
| KR100840957B1 (ko) | 2008-06-24 |
| AU9683298A (en) | 1999-04-27 |
| KR100804558B1 (ko) | 2008-02-20 |
| JP5180125B2 (ja) | 2013-04-10 |
| US6362173B1 (en) | 2002-03-26 |
| CA2302586A1 (en) | 1999-04-15 |
| DE69835225D1 (de) | 2006-08-24 |
| CN1528315A (zh) | 2004-09-15 |
| KR20010024431A (ko) | 2001-03-26 |
| NO20001744L (no) | 2000-04-05 |
| IL135469A0 (en) | 2001-05-20 |
| NO20001744D0 (no) | 2000-04-05 |
| CN1919199A (zh) | 2007-02-28 |
| CN1272788A (zh) | 2000-11-08 |
| JP2001518509A (ja) | 2001-10-16 |
| AU747956B2 (en) | 2002-05-30 |
| IL135469A (en) | 2007-03-08 |
| KR20070032822A (ko) | 2007-03-22 |
| ATE332696T1 (de) | 2006-08-15 |
| EP1023074B1 (en) | 2006-07-12 |
| US6150349A (en) | 2000-11-21 |
| JP2009132743A (ja) | 2009-06-18 |
| JP2009051858A (ja) | 2009-03-12 |
| NZ503250A (en) | 2001-09-28 |
| CY1106330T1 (el) | 2011-10-12 |
| WO1999017779A1 (en) | 1999-04-15 |
| CN1187053C (zh) | 2005-02-02 |
| EP1023074A1 (en) | 2000-08-02 |
| ES2268792T3 (es) | 2007-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1023074T3 (da) | Fremgangsmåder til behandling af psykose forbundet med glucocorticoid-relateret dysfunktion | |
| DK1408981T3 (da) | Fremgangsmåder til forebyggelse af vægtforögelse som fölge af antipsykotiske midler | |
| NO20031179D0 (no) | Chemokin-reseptorbindende heterocykliske forbindelser | |
| DK1339678T3 (da) | Selektive agonister til EP4-receptor til behandling af osteoporose | |
| IL139672A (en) | Glucocorticoid receptor antagonists for the tretment of dementia | |
| ATE328871T1 (de) | 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten | |
| SG149693A1 (en) | Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use | |
| DE69929235D1 (de) | Spiro-indole als y5-rezeptor antagonisten | |
| EP1351670A4 (en) | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS WITH NMDA RECEPTOR ANTAGONISTS | |
| DE69533180D1 (de) | Steroidrezeptor-Modulator Verbindungen und Methoden | |
| WO2007027734A3 (en) | Bicyclic and bridged nitrogen heterocycles | |
| CL2004000545A1 (es) | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul | |
| CL2004000449A1 (es) | Compuestos derivados de imidazol-4-il-etinil-piridina, para tratar trastornos mediados por el receptor mglur5; procedimiento de preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en | |
| HUP0201184A3 (en) | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | |
| NO994850L (no) | Farmakologiske midler | |
| DK1313485T3 (da) | Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion | |
| UY28417A1 (es) | Antagonistas de los receptores muscarinicos de la acetilcolina | |
| HK1047050A1 (zh) | 治疗轻度智力机能缺陷的方法 | |
| SV2002000005A (es) | Heterociclos 2-arilimino substituidos y composiciones que los contienen para usar como agentes que ligan el receptor de la progesterona ref. 5048p1-sv | |
| ATE411013T1 (de) | Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom | |
| DE69803883D1 (de) | Neue verbindungen, welche antagonisten sind für p2-purinorezeptor 7-transmembran (tm) g-protein gekoppelte rezeptoren | |
| TR200100240T2 (tr) | Anksiyete bozukluklarının tedavisi | |
| SV2003000849A (es) | Antagonistas de receptores de histamina ref.pcs10963aksr/bb | |
| IL158744A0 (en) | Methods for treating delirium using glucocorticoid receptor-specific antagonists | |
| AU2002219192A1 (en) | Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |